npj Precision Oncology (Mar 2024)

Biallelic EPCAM deletions induce tissue-specific DNA repair deficiency and cancer predisposition

  • V. J. Forster,
  • M. Aronson,
  • C. Zhang,
  • J. Chung,
  • S. Sudhaman,
  • M. A. Galati,
  • J. Kelly,
  • L. Negm,
  • A. B. Ercan,
  • L. Stengs,
  • C. Durno,
  • M. Edwards,
  • M. Komosa,
  • L. E. Oldfield,
  • N. M. Nunes,
  • S. Pedersen,
  • J. Wellum,
  • I. Siddiqui,
  • V. Bianchi,
  • B. R. Weil,
  • V. L. Fox,
  • T. J. Pugh,
  • J. Kamihara,
  • U. Tabori

DOI
https://doi.org/10.1038/s41698-024-00537-6
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 7

Abstract

Read online

Abstract We report a case of Mismatch Repair Deficiency (MMRD) caused by germline homozygous EPCAM deletion leading to tissue-specific loss of MSH2. Through the use of patient-derived cells and organoid technologies, we performed stepwise in vitro differentiation of colonic and brain organoids from reprogrammed EPCAMdel iPSC derived from patient fibroblasts. Differentiation of iPSC to epithelial-colonic organoids exhibited continuous increased EPCAM expression and hypermethylation of the MSH2 promoter. This was associated with loss of MSH2 expression, increased mutational burden, MMRD signatures and MS-indel accumulation, the hallmarks of MMRD. In contrast, maturation into brain organoids and examination of blood and fibroblasts failed to show similar processes, preserving MMR proficiency. The combined use of iPSC, organoid technologies and functional genomics analyses highlights the potential of cutting-edge cellular and molecular analysis techniques to define processes controlling tumorigenesis and uncovers a new paradigm of tissue-specific MMRD, which affects the clinical management of these patients.